To mark the 25the At the World Congress of Dermatology (WCD), held in Singapore from July 4 to 7, Pierre Fabre's Patient Relations Department presented the ALL project, a large-scale survey, the largest ever carried out in dermatology.
This project, launched at the end of 2022 with the help of Emma, aims to collect data on all skin types (ALL Skins), all skin diseases (ALL Dermatoses) and all phototypes (ALL Colors) in order to build the largest international private database.
Some 50,552 people from the adult populations of 20 countries (representing over 50 % of the world's population) on five continents answered the 65 ALL project questions.
The main themes addressed relate to the prevalence and impact of pathologies, but also to the behaviors, care pathways and needs of patients affected by one or more dermatoses such as atopic dermatitis, psoriasis, acne, rosacea or vitiligo (see Appendix 1).
The strength of this study lies in the considerable scope of the data collected, and their representativeness: respondents were drawn from samples proportional to the population of each country (see Appendix 2), enabling a highly reliable analysis of needs on a global scale, by geographical territory.
The ALL database has been built with results analyzed over time (longitudinal analysis), over a five-year period (2023-2027). The 3.3 million data points will be used to identify the information essential to a better understanding of patients' experiences.
"The creation of this database, exceptional in its geographical coverage, confirms our commitment to working alongside healthcare professionals worldwide to help improve the quality of life of patients suffering from skin pathologies. Better understanding their expectations will enable us to orientate our way of working and innovate to better support them in their dermatological care.said Núria Perez Cullel, Medical and Patient/Consumer Relations Director at Pierre Fabre.
More than one person in three suffers from a skin disease, yet health and prevention policies do not consider dermatology to be a public health priority. The ALL project aims to provide a global overview of the prevalence of major skin diseases and their consequences, in order to raise awareness among all stakeholders. Patients suffering from dermatological diseases need more support, and it is essential to succeed in convincing public authorities to attach greater importance to dermatoses in prevention programs.
This unique project has already won the support of internationally renowned opinion leaders: Professor Jean Hilaire Saurat of the University of Geneva for acne, Professor Gil Yosipovitch of the University of Miami, for pruritus, Professors Henry LIM of the University of Detroit and Khaled Ezzedine, dermatologist at APH Paris, for photoprotection, Professor Julien Seneschal, dermatologist at Bordeaux University Hospital for vitiligo and Professor Marie Aleth Richard, dermatologist at APH Marseille and former president of the SFD.
Data from the ALL study will also be shared with patient associations to help them make their case to the general public, healthcare professionals and the authorities. Seven patient associations have already been involved in this process in France and abroad.
"For healthcare professionals, the ALL project is unique. Thanks to its methodology, it will enable us to describe for the first time the perceived prevalence of pruritus worldwide, regardless of patients' ethnicity, gender, age or region!" said Professor Gil Yosipovitch, Director of the Miami Itch Center (Dr. Phillip Frost Dept. of Dermatology, Miller School of Medicine, Miami USA).
Appendix 1:
List of subjects studied
Acne, psoriasis, rosacea, eczema, lentigo, skin cancers, vitiligo, hair and nail disorders, wounds/healing, pain and pruritus, aesthetic procedures, oral care disorders, sun protection.
Appendix 2:
Sample sizes by country
5000 people in China; 5000 people in the USA; 4001 people in Brazil; 4001 people in Italy; 4000 people in France; 4000 people in Germany; 4000 people in Spain; 3000 people in India; 2500 people in Canada; 2500 people in Mexico; 2500 people in Poland; 2500 people in South Korea; 2000 people in Australia; 1000 people in Denmark; 1000 people in Israel; 1000 people in Portugal; 1000 people in South Africa; 750 people in the United Arab Emirates; 500 people in Kenya; 300 people in Senegal.
